Quantum Biopharma Files 6-K Report

Ticker: QNTM · Form: 6-K · Filed: Oct 8, 2025 · CIK: 1771885

Quantum Biopharma Ltd. 6-K Filing Summary
FieldDetail
CompanyQuantum Biopharma Ltd. (QNTM)
Form Type6-K
Filed DateOct 8, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, regulatory-filing

TL;DR

Quantum Biopharma (fka FSD Pharma) filed a 6-K on Oct 8, 2025, confirming 20-F annual report filings.

AI Summary

Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on October 8, 2025. The company, incorporated in A6 with its principal executive office in Toronto, Ontario, is reporting under the 1934 Act. This filing is for the month of October 2025 and indicates the company files annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Quantum Biopharma's ongoing reporting status.

Risk Assessment

Risk Level: low — This is a routine administrative filing (Form 6-K) and does not contain new material financial or operational information.

Key Players & Entities

  • Quantum Biopharma Ltd. (company) — Filer of the report
  • FSD Pharma Inc. (company) — Former name of the registrant
  • October 8, 2025 (date) — Filing date
  • Toronto, Ontario (location) — Location of principal executive office
  • Form 20-F (document) — Annual report filing type
  • Form 6-K (document) — Type of filing

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K is to report information for the month of October 2025 and to indicate that the registrant files annual reports under cover of Form 20-F.

What was Quantum Biopharma Ltd. previously known as?

Quantum Biopharma Ltd. was formerly known as FSD Pharma Inc.

Where is Quantum Biopharma Ltd.'s principal executive office located?

Quantum Biopharma Ltd.'s principal executive office is located at 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9.

Under which SEC Act is this filing made?

This filing is made under the Securities Exchange Act of 1934.

Does Quantum Biopharma Ltd. file annual reports?

Yes, Quantum Biopharma Ltd. files annual reports under cover of Form 20-F.

Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2025-10-08 08:00:17

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: October 8, 2025 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated October 8, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.